← ANALYST RATINGS · TIPRANKS
LENZ Therapeutics (LENZ): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy1 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $18.33, the highest $38.00, the lowest $7.00. The average is +460.7% from the last price of $3.27.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +7.0% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +7.0% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +7.0% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +7.0% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +7.0% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | +7.0% | Reiterated | 01.10.26on TipRanks 05:05 | — | |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $20.00 → $10.00−50.0% | Buy | +205.8% | Reiterated | 13.08.26on TipRanks Aug 12 07:05 | −3.5%next day −9.4% · 5 days −1.9% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $7.00 | Hold | +114.1% | Downgrade | 12.08.26on TipRanks 22:05 | −9.4%next day +3.0% · 5 days +3.3% | ↗ |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 12.08.26on TipRanks 10:15 | −3.5%next day −9.4% · 5 days −1.9% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $12.00 → $7.00−41.7% | Hold | +114.1% | Reiterated | 12.08.26on TipRanks 07:05 | −3.5%next day −9.4% · 5 days −1.9% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $38.00 | Buy | +1,062.1% | Reiterated | 12.08.26on TipRanks 06:25 | −3.5%next day −9.4% · 5 days −1.9% | ↗ |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | $60.00 | Buy | +1,734.9% | Assigned | 12.08.26on TipRanks 01:20 | −3.5%next day −9.4% · 5 days −1.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering LENZ Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.40 at a price of $3.84 (+535.4%); now: $24.40 at $3.27 (+646.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 5 | 4 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.91 (from $-1.02 to $-0.66). Last quarter: $-1.02.
Sales
Next quarter’s sales estimate — $5M (from $2M to $9M). Last quarter: $5M.
Best top-analyst consensus in the sector · Healthcare
About LENZ Therapeutics
- CEO: Evert Schimmelpennink
- Employees: 152
- 201 Lomas Santa Fe Drive, Solana Beach, CA, 92075, US
- www.lenz-tx.com
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Data from the stock’s TipRanks forecast page, read 54 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗